ClinicalTrials.gg
Active, not recruitingNCT05854069Updated Nov 3, 2026

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

An interventional study of FAMS-T1D and Digital resources for diabetes in Type 1 Diabetes, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Vanderbilt University Medical Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center — 5 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Vanderbilt University Medical Center.

Planned enrollment
5th of 14
140 · median 50
Started
2023
the only one that year
No phase
11 of 15
3 open now
Registered
10th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 11 with no phase, and was the 10th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

5 of the 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 1 by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

Read the detailed description

FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication).

Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.

03

Conditions studied

  • Type 1 Diabetes

Keywords

  • Continuous glucose monitor
  • Social support
  • Goal setting
  • Diabetes distress
  • Hemoglobin A1c
  • Time in range
  • Emerging adults
  • Family support
  • Text message
  • Mobile health
04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

PERSONS WITH DIABETES

  • Ages 18-24
  • Have a diagnosis of T1D and has been taking insulin for at least one year
  • Comfortable sending and receiving texts
  • Can speak, read, and write in English
  • Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2)
  • Using a continuous glucose monitor (CGM)

SUPPORT PERSONS

  • Age 18 or older
  • Can speak, read, and write in English or Spanish
  • Comfortable sending and receiving texts

Exclusion criteria

Exclusion Criteria:

PERSONS WITH DIABETES

  • Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness)
  • Plans to live outside the country during the study period

SUPPORT PERSONS

  • Shares a phone with the person with diabetes
  • Plans to live outside of the country during the study period
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    FAMS-T1D

    Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

    Behavioral: FAMS-T1D · Behavioral: Digital resources for diabetes

  • Placebo comparator
    Digital resources for diabetes

    All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

    Behavioral: Digital resources for diabetes

Interventions

  • BehavioralFAMS-T1D

    FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled. Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.

    Also known as: Family/friend Activation to Motivate Self-Care for those with Type 1 Diabetes

  • BehavioralDigital resources for diabetes

    Quality digital resources about diabetes management provided upon enrollment and during the study.

06

What researchers measure

Primary outcomes

  1. CGM frequency of use during the intervention period

    Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better

    Time frame: Baseline and 6 months post-baseline

  2. CGM frequency of use during the intervention period

    Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)

    Time frame: Baseline and 6 months post-baseline

  3. Gaps in CGM use

    Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

    Time frame: 6 months post-baseline

Secondary outcomes

  1. CGM behavioral responses during the intervention period

    Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)

    Time frame: Baseline and 6 months post-baseline

  2. Barriers to CGM use during the intervention period

    Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

    Time frame: Baseline and 6 months post-baseline

  3. Barriers to CGM use during the intervention period

    Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

    Time frame: Baseline and 6 months post-baseline

  4. CGM satisfaction during the intervention period

    Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)

    Time frame: Baseline and 6 months post-baseline

Other outcomes

  1. Data sharing during the intervention period

    Number of data sharing relationships, between groups; more is better

    Time frame: 6 months post-baseline

  2. Satisfaction with data-sharing relationships

    Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better

    Time frame: 6 months post-baseline

07

Study locations

2 sites
08

References and documents

Publications

  • Berg CA, Wiebe DJ, Mansfield JH, Raymond JK, Sandoval MV, LeStourgeon LM, Roddy MK, Ellis EB, Darow EL, Gonzalez F, Boyd SA, Spieker AJ, Butner JE, Greevy RA, Mayberry LS. Randomized controlled trial evaluating a mHealth intervention to optimize self- and social-regulation for emerging adults with type 1 diabetes (FAMS-T1D): protocol and lessons learned. Contemp Clin Trials. 2026 Oct 25:108508. doi: 10.1016/j.cct.2026.108508. Online ahead of print. PubMed 42927777 ↗

Individual participant data

Plan to share: Yes — After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.

Access criteria: Contact the principal investigator

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 45 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 11, 2023
StartActual
Apr 30, 2023
Primary completionEst.
Jan 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42927777 ↗
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42927777 ↗
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05854069
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, University of Utah, University of California, Merced, Children's Hospital Los Angeles
Responsible party
Lindsay Mayberry (Principle Investigator, Vanderbilt University Medical Center) — Principal investigator
First posted
May 11, 2023
Start date
Apr 30, 2023
Primary completion
Jan 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Nov 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion